CB1 cannabinoid receptor ligands

被引：66

作者：

Thakur, GA

Nikas, SP

Makriyannis, A ^{[1
]}

机构：

[1] Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT 06269 USA

[2] Univ Connecticut, Ctr Drug Discovery, Storrs, CT 06269 USA

[3] Univ Connecticut, Dept Mol & Cell Biol, Storrs, CT 06269 USA

[4] Univ Connecticut, Inst Mat Sci, Storrs, CT 06269 USA

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2005年 / 5卷 / 07期

关键词：

cannabinoid receptors; CB1; agonists; antagonists; selectivity;

D O I：

10.2174/1389557054368772

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The CB1 receptor is expressed in the central nervous system and numerous other tissues including heart, lung and uterus and has been recognized as an important therapeutic target for pain, appetite modulation, glaucoma, multiple sclerosis and other indications. An interesting feature of this GPCR is its ability to be activated by a number of structurally different classes of compounds, thus, raising the possibility of multiple activated forms of the receptor. Understanding of the structure-activity relationships of cannabinergic ligands has paved the road for the development of novel ligands exhibiting receptor subtype selectivity and efficacy. This review highlights the important CB1 cannabinergic ligands developed to date.

引用

收藏

页码：631 / 640

页数：10

相关论文

共 138 条

[1] (R)-METHANANDAMIDE - A CHIRAL NOVEL ANANDAMIDE POSSESSING HIGHER POTENCY AND METABOLIC STABILITY [J].

ABADJI, V ;

LIN, SY ;

TAHA, G ;

GRIFFIN, G ;

STEVENSON, LA ;

PERTWEE, RG ;

MAKRIYANNIS, A .

JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (12) :1889-1893

[2] Isolation and expression of a mouse CB1 cannabinoid receptor gene - Comparison of binding properties with those of native CB1 receptors in mouse brain and N18TG2 neuroblastoma cells [J].

Abood, ME ;

Ditto, KE ;

Noel, MA ;

Showalter, VM ;

Tao, Q .

BIOCHEMICAL PHARMACOLOGY, 1997, 53 (02) :207-214

[3]

ADAMS IB, 1995, J PHARMACOL EXP THER, V273, P1172

[4] NEW ANALOGS OF TETRAHYDROCANNABINOL .19. [J].

ADAMS, R ;

HARFENIST, M ;

LOEWE, S .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1949, 71 (05) :1624-1628

[5] Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides [J].

Barg, J ;

Fride, E ;

Hanus, L ;

Levy, R ;

MatusLeibovitch, N ;

Heldman, E ;

Bayewitch, M ;

Mechoulam, R ;

Vogel, Z .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 287 (02) :145-152

[6] Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor [J].

Barnett-Norris, J ;

Hurst, DP ;

Lynch, DL ;

Guarnieri, F ;

Makriyannis, A ;

Reggio, PH .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (17) :3649-3659

[7] N-acyl-dopamines:: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo [J].

Bisogno, T ;

Melck, D ;

Bobrov, MY ;

Gretskaya, NM ;

Bezuglov, VV ;

De Petrocellis, L ;

Di Marzo, V .

BIOCHEMICAL JOURNAL, 2000, 351 (03) :817-824

[8] Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide [J].

Boger, DL ;

Patterson, JE ;

Guan, XJ ;

Cravatt, BF ;

Lerner, RA ;

Gilula, NB .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (09) :4810-4815

[9] Structural requirements for 5-HT2A and 5-HT1A serotonin receptor potentiation by the biologically active lipid oleamide [J].

Boger, DL ;

Patterson, JE ;

Jin, Q .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (08) :4102-4107

[10] MICROSOMAL CYTOCHROME P450-MEDIATED LIVER AND BRAIN ANANDAMIDE METABOLISM [J].

BORNHEIM, LM ;

KIM, KY ;

CHEN, BL ;

CORREIA, MA .

BIOCHEMICAL PHARMACOLOGY, 1995, 50 (05) :677-686

← 1 2 3 4 5 6 7 8 9 10 →